AbbVie drug approval sets up competition with Biohaven in migraine prevention
AbbVie drug Quilpta, developed specifically for migraine prevention, is now FDA approved, the latest product in a new class of migraine medicines. The AbbVie drug is the second oral migraine prevention drug that the FDA has approved this year.